8-乙酰基-3-甲基-3,8-二氮杂双环[3.2.1]辛烷 | 63978-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 8-乙酰基-3-甲基-3,8-二氮杂双环[3.2.1]辛烷
• 英文名称: 3-Methyl-8-acetyl-3,8-diaza-bicyclo<3.2.1>octan
• 英文别名: 8-acetyl-3-methyl-3,8-diaza-bicyclo[3.2.1]octane；8-Acetyl-3-methyl-3,8-diazabicyclo(3.2.1)octane；1-(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)ethanone
• CAS: 63978-07-4
• 化学式: C₉H₁₆N₂O
• 分子量: 168.239
• InChiKey: SWUJAINMZHBCAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

文献信息

• Inhibitors of the Renal Outer Medullary Potassium Channel
  申请人：Pasternak Alexander

  公开号：US20130217680A1

  公开（公告）日：2013-08-22

  This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  本发明涉及具有结构式（I）的化合物及其药学上可接受的盐，它们是肾外髓质钾（ROMK）通道（Kir 1.1）的抑制剂。公式I的化合物可用作利尿剂和钠利尿剂，因此可用于治疗和预防由过度盐和水潴留引起的疾病，包括高血压和慢性和急性心力衰竭等心血管疾病。
• Therapeutic compounds and uses thereof
  申请人：GENENTECH, INC.

  公开号：US10308614B2

  公开（公告）日：2019-06-04

  The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

  本发明涉及式（I）化合物： 及其盐类，其中R1-R4具有说明书中定义的任何值，以及其组合物和用途。这些化合物可用作 BRG1、BRM 和/或 PB1 的抑制剂。还包括包含式（I）化合物或其药学上可接受的盐的药物组合物，以及使用此类化合物和盐治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病的方法。
• Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
  申请人：Rodin Therapeutics, Inc.

  公开号：US10421756B2

  公开（公告）日：2019-09-24

  This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

  本发明提供的化合物是 HDAC2 的抑制剂。 这些化合物（例如，根据式（I）的化合物或化合物100-175中的任意一种）相应地可用于治疗、减轻或预防受试者的疾病，如神经系统疾病、记忆或认知功能障碍或损伤、学习障碍、真菌疾病或感染、炎症性疾病、血液病或肿瘤性疾病，或用于改善记忆或治疗、减轻或预防记忆力减退或损伤。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180086720A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds of formula (I): and salts thereof, wherein: R 1 -R 4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
• US9056859B2
  申请人：——

  公开号：US9056859B2

  公开（公告）日：2015-06-16